BG104427A - Use of ketolides for preparing arterial thrombotic complications related to atherosclerosis - Google Patents

Use of ketolides for preparing arterial thrombotic complications related to atherosclerosis

Info

Publication number
BG104427A
BG104427A BG104427A BG10442700A BG104427A BG 104427 A BG104427 A BG 104427A BG 104427 A BG104427 A BG 104427A BG 10442700 A BG10442700 A BG 10442700A BG 104427 A BG104427 A BG 104427A
Authority
BG
Bulgaria
Prior art keywords
ketolides
atherosclerosis
complications related
thrombotic complications
arterial thrombotic
Prior art date
Application number
BG104427A
Other languages
Bulgarian (bg)
English (en)
Inventor
Francis Petit
Francoise Vacheron
Original Assignee
Hoechst Marion Roussel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel filed Critical Hoechst Marion Roussel
Publication of BG104427A publication Critical patent/BG104427A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
BG104427A 1997-11-17 2000-05-11 Use of ketolides for preparing arterial thrombotic complications related to atherosclerosis BG104427A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9714358A FR2771008B1 (fr) 1997-11-17 1997-11-17 Utilisation des ketolides pour la preparation de compositions pharmaceutiques destinees a prevenir les complications thrombotiques arterielles liees a l'atherosclerose
PCT/FR1998/002436 WO1999025365A1 (fr) 1997-11-17 1998-11-16 Utilisation des ketolides pour prevenir les complications thrombotiques arterielles liees a l'atherosclerose

Publications (1)

Publication Number Publication Date
BG104427A true BG104427A (en) 2001-02-28

Family

ID=9513423

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104427A BG104427A (en) 1997-11-17 2000-05-11 Use of ketolides for preparing arterial thrombotic complications related to atherosclerosis

Country Status (35)

Country Link
US (1) US20080139489A1 (cg-RX-API-DMAC7.html)
EP (1) EP1030673B1 (cg-RX-API-DMAC7.html)
JP (1) JP4550273B2 (cg-RX-API-DMAC7.html)
KR (1) KR20010032130A (cg-RX-API-DMAC7.html)
CN (1) CN1286633A (cg-RX-API-DMAC7.html)
AP (1) AP1196A (cg-RX-API-DMAC7.html)
AR (1) AR014119A1 (cg-RX-API-DMAC7.html)
AT (1) ATE271875T1 (cg-RX-API-DMAC7.html)
AU (1) AU744419B2 (cg-RX-API-DMAC7.html)
BG (1) BG104427A (cg-RX-API-DMAC7.html)
BR (1) BR9814199A (cg-RX-API-DMAC7.html)
CA (1) CA2312021C (cg-RX-API-DMAC7.html)
DE (1) DE69825308T2 (cg-RX-API-DMAC7.html)
DZ (1) DZ2654A1 (cg-RX-API-DMAC7.html)
EA (1) EA003322B1 (cg-RX-API-DMAC7.html)
EE (1) EE04095B1 (cg-RX-API-DMAC7.html)
ES (1) ES2224446T3 (cg-RX-API-DMAC7.html)
FR (1) FR2771008B1 (cg-RX-API-DMAC7.html)
GE (1) GEP20032968B (cg-RX-API-DMAC7.html)
HR (1) HRP20000314A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0004507A3 (cg-RX-API-DMAC7.html)
ID (1) ID24940A (cg-RX-API-DMAC7.html)
IL (1) IL136149A0 (cg-RX-API-DMAC7.html)
MA (1) MA26566A1 (cg-RX-API-DMAC7.html)
NO (1) NO20002435L (cg-RX-API-DMAC7.html)
NZ (1) NZ504305A (cg-RX-API-DMAC7.html)
OA (1) OA11411A (cg-RX-API-DMAC7.html)
PL (1) PL340373A1 (cg-RX-API-DMAC7.html)
SK (1) SK7042000A3 (cg-RX-API-DMAC7.html)
TN (1) TNSN98206A1 (cg-RX-API-DMAC7.html)
TR (1) TR200001384T2 (cg-RX-API-DMAC7.html)
TW (1) TW472061B (cg-RX-API-DMAC7.html)
WO (1) WO1999025365A1 (cg-RX-API-DMAC7.html)
YU (1) YU29600A (cg-RX-API-DMAC7.html)
ZA (1) ZA9810357B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777282B1 (fr) * 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
ATE344269T1 (de) * 1998-12-10 2006-11-15 Pfizer Prod Inc Carbamat und carbazat ketolid antibiotika
DK1147121T3 (da) * 1999-01-27 2004-04-13 Pfizer Prod Inc Ketolidantibiotika
EP1114826A3 (en) * 1999-12-29 2001-10-31 Pfizer Products Inc. Novel antibacterial and prokinetic macrolides
HUP0300370A3 (en) 2000-04-04 2005-07-28 Smithkline Beecham Plc 2-hydroxy-mutilin carbamate derivatives of antibacterial effect process for preparation and pharmaceutical compositions containing them
JP2004323414A (ja) * 2003-04-24 2004-11-18 Japan Science & Technology Agency 14員環マクロライド化合物を利用した、血管平滑筋の増殖に起因する疾患治療剤
GB0402578D0 (en) * 2004-02-05 2004-03-10 Cambridge Theranostics Ltd Methods of treatment of atherosclerosis
KR20130120458A (ko) * 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2249892A (en) * 1991-06-14 1993-01-12 Board Of Regents Of The University Of Washington, The Diagnosis and treatment of arterial chlamydial granuloma
FR2718450B1 (fr) * 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) * 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2742757B1 (fr) * 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US6271255B1 (en) * 1996-07-05 2001-08-07 Biotica Technology Limited Erythromycins and process for their preparation
GB9621771D0 (en) * 1996-10-18 1996-12-11 St George S Enterprises Ltd Method of treatment of heart disease
FR2757168B1 (fr) * 1996-12-12 1999-06-11 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
EP0895999A1 (en) * 1997-08-06 1999-02-10 Pfizer Products Inc. C-4" substituted macrolide antibiotics

Also Published As

Publication number Publication date
NO20002435D0 (no) 2000-05-11
YU29600A (sh) 2003-02-28
NO20002435L (no) 2000-07-07
JP4550273B2 (ja) 2010-09-22
WO1999025365A1 (fr) 1999-05-27
CA2312021A1 (fr) 1999-05-27
BR9814199A (pt) 2000-09-26
EP1030673A1 (fr) 2000-08-30
DE69825308D1 (de) 2004-09-02
EE200000244A (et) 2001-06-15
DE69825308T2 (de) 2005-08-04
AU744419B2 (en) 2002-02-21
DZ2654A1 (fr) 2003-03-22
SK7042000A3 (en) 2000-12-11
JP2001523644A (ja) 2001-11-27
TNSN98206A1 (fr) 2005-03-15
AU1242599A (en) 1999-06-07
HUP0004507A3 (en) 2001-12-28
CN1286633A (zh) 2001-03-07
AP2000001825A0 (en) 2000-06-30
ES2224446T3 (es) 2005-03-01
GEP20032968B (en) 2003-05-27
KR20010032130A (ko) 2001-04-16
AR014119A1 (es) 2001-02-07
EA003322B1 (ru) 2003-04-24
TW472061B (en) 2002-01-11
ZA9810357B (en) 1999-11-12
TR200001384T2 (tr) 2001-06-21
EP1030673B1 (fr) 2004-07-28
PL340373A1 (en) 2001-01-29
HRP20000314A2 (en) 2001-02-28
CA2312021C (fr) 2008-08-26
US20080139489A1 (en) 2008-06-12
EE04095B1 (et) 2003-08-15
HUP0004507A1 (hu) 2001-05-28
AP1196A (en) 2003-08-18
EA200000531A1 (ru) 2000-10-30
NZ504305A (en) 2002-11-26
FR2771008B1 (fr) 2000-04-28
ATE271875T1 (de) 2004-08-15
IL136149A0 (en) 2001-05-20
ID24940A (id) 2000-08-31
MA26566A1 (fr) 2004-12-20
OA11411A (fr) 2004-04-20
FR2771008A1 (fr) 1999-05-21

Similar Documents

Publication Publication Date Title
AU655769B2 (en) Novel use of modafinil
BG104315A (en) Prostaglandine agonists and their application for the treatment of osteal diseases
AU2092988A (en) Dental calculus inhibiting compositions
IL141157A0 (en) Salt form of pantoprazole and pharmaceutical compositions containing the same
AU4035595A (en) Crystalline paclitaxel hydrates
HU9603140D0 (en) Pharmaceutical compositions catalyzing decomposition of peroxy-nitrite
AU4851397A (en) Compositions for the preparation of leather
HUP9903166A3 (en) Medicinal compositions for the prophylaxis or treatment of arteriosclerosis
HUP0004071A3 (en) Pharmaceutical compositions comprising prostaglandin derivatives
GB2234171B (en) N-Acetyl-cysteine compositions of enhanced bioavailability
AU2998095A (en) Pharmaceutical compositions comprising vitamin-d analogs
YU29600A (sh) Korišćenje ketolida za dobijanje farmaceutskih preparata za prevenciju trombičnih arterijskih komplikacija povezanih sa arterosklerozom
AU8168998A (en) Synthesis of dihydrohonokiol compositions
BG103649A (en) Method for the preparation of eprosartan
AU6849198A (en) Neurotrypsin
BG103650A (en) Method for the preparation of eprosartan
AU3191597A (en) Novel medicinal compositions of hydropyridines
GR1002576B (el) Φαρμακευτικες συνθεσεις και μια μεθοδος παρασκευης τους.
HUP0003159A3 (en) The use of n-monosubstituted-3-oxo-4-aza-5alpha-androst-1-en-17betha-carboxamides for the preparation of pharmaceutical compositions
EP0868430A4 (en) THERAPEUTIC COMPOSITIONS
TW344650B (en) Fungicidal compositions and the process for the preparation thereof
WO2000029015A3 (de) BEEINFLUSSUNG DER ANGIOGENESE DURCH CD66a
GB9508785D0 (en) Novel compositions
HUP0001499A3 (en) Use of 7alpha-methyl-17alpha-ethynyl-estrane derivative for producing pharmaceutical compositions for the treatment of atherosclerosis
PL313116A1 (en) Application of n-alkalated 1,4-dihydropridinocarboxylic esters as drugs